These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 10093625

  • 1. Epirubicin, alone or in combination chemotherapy, for metastatic breast cancer. Provincial Breast Cancer Disease Site Group and the Provincial Systemic Treatment Disease Site Group.
    Findlay BP, Walker-Dilks C.
    Cancer Prev Control; 1998 Jun; 2(3):140-6. PubMed ID: 10093625
    [Abstract] [Full Text] [Related]

  • 2. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
    Seymour L, Bramwell V, Moran LA.
    Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
    [Abstract] [Full Text] [Related]

  • 3. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
    Rusthoven J, Bramwell V, Stephenson B.
    Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
    [Abstract] [Full Text] [Related]

  • 4. Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial Genitourinary Cancer Disease Site Group.
    Brundage MD, Crook JM, Lukka H.
    Cancer Prev Control; 1998 Apr; 2(2):79-87. PubMed ID: 9765768
    [Abstract] [Full Text] [Related]

  • 5. Use of vinorelbine in non-small-cell lung cancer. Provincial Lung Disease Site Group.
    Goss GD, Logan DM, Newman TE, Evans WK.
    Cancer Prev Control; 1997 Apr; 1(1):28-38. PubMed ID: 9765724
    [Abstract] [Full Text] [Related]

  • 6. Chemotherapy in stage IV (metastatic) non-small-cell lung cancer. Provincial Lung Disease Site Group.
    Lopez PG, Stewart DJ, Newman TE, Evans WK.
    Cancer Prev Control; 1997 Apr; 1(1):18-27. PubMed ID: 9765723
    [Abstract] [Full Text] [Related]

  • 7. Use of preoperative chemotherapy with or without postoperative radiotherapy in technically resectable stage IIIA non-small-cell lung cancer. Provincial Lung Cancer Disease Site Group.
    Goss G, Paszat L, Newman TE, Evans WK, Browman G.
    Cancer Prev Control; 1998 Feb; 2(1):32-9. PubMed ID: 9765764
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group.
    Figueredo A, Germond C, Maroun J, Browman G, Walker-Dilks C, Wong S.
    Cancer Prev Control; 1997 Dec; 1(5):379-92. PubMed ID: 9765760
    [Abstract] [Full Text] [Related]

  • 9. Surgical management of early stage invasive breast cancer (stage I and II). Provincial Breast Disease Site Group.
    Mirsky D, O'Brien SE, McCready DR, Newman TE, Whelan TJ, Levine MN.
    Cancer Prev Control; 1997 Dec; 1(1):10-7. PubMed ID: 9765722
    [Abstract] [Full Text] [Related]

  • 10. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
    Lück HJ, Thomssen C, du Bois A, Untch M, Lisboa B, Köhler G, Diergarten K.
    Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
    [Abstract] [Full Text] [Related]

  • 11. Liposomal doxorubicin in breast cancer: new preparation. Much ado about nothing.
    Prescrire Int; 2003 Jun; 12(65):93-5. PubMed ID: 12825572
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.
    Dombernowsky P, Gehl J, Boesgaard M, Jensen TP, Jensen BV.
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):13-8. PubMed ID: 8629030
    [Abstract] [Full Text] [Related]

  • 14. Doxorubicin liposomal pegylated: new preparation. Breast cancer: not just a question of short-term cardiac effects.
    Prescrire Int; 2004 Jun; 13(71):90-1. PubMed ID: 15233142
    [Abstract] [Full Text] [Related]

  • 15. Risk of acute leukemia following epirubicin-based adjuvant chemotherapy: a report from the National Cancer Institute of Canada Clinical Trials Group.
    Crump M, Tu D, Shepherd L, Levine M, Bramwell V, Pritchard K.
    J Clin Oncol; 2003 Aug 15; 21(16):3066-71. PubMed ID: 12915595
    [Abstract] [Full Text] [Related]

  • 16. Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.
    Luck HJ, Thomssen C, duBois A, Lisboa BW, Untch M, Kuhnle H, Konecny G, Janicke F, Meerpohl HG, Lindner C, Hecker D, Diergarten K.
    Semin Oncol; 1996 Feb 15; 23(1 Suppl 1):33-6. PubMed ID: 8629034
    [Abstract] [Full Text] [Related]

  • 17. Epirubicin as adjuvant therapy in breast cancer.
    Earl H, Iddawela M.
    Expert Rev Anticancer Ther; 2004 Apr 15; 4(2):189-95. PubMed ID: 15056049
    [Abstract] [Full Text] [Related]

  • 18. Phase III study of N,N-diethyl-2-[4-(phenylmethyl) phenoxy]ethanamine (BMS-217380-01) combined with doxorubicin versus doxorubicin alone in metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA.19.
    Reyno L, Seymour L, Tu D, Dent S, Gelmon K, Walley B, Pluzanska A, Gorbunova V, Garin A, Jassem J, Pienkowski T, Dancey J, Pearce L, MacNeil M, Marlin S, Lebwohl D, Voi M, Pritchard K, National Cancer Institute of Canada Clinical Trials Group Study MA.19.
    J Clin Oncol; 2004 Jan 15; 22(2):269-76. PubMed ID: 14722035
    [Abstract] [Full Text] [Related]

  • 19. [Standards, options and recommendations: concomitant radiochemotherapy for cancer of the cervix: a critical analysis of the literature and update of SOR].
    Haie-Meder C, Fervers B, Chauvergne J, Fondrinier E, Lhommé C, Guastalla JP, Resbeut M.
    Bull Cancer; 1999 Oct 15; 86(10):829-41. PubMed ID: 10572234
    [Abstract] [Full Text] [Related]

  • 20. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients.
    Ryberg M, Nielsen D, Cortese G, Nielsen G, Skovsgaard T, Andersen PK.
    J Natl Cancer Inst; 2008 Aug 06; 100(15):1058-67. PubMed ID: 18664656
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.